IDEAYA Biosciences Common Stock share price logo

IDEAYA Biosciences Common Stock

NASDAQ: IDYA

Mid Cap

$34.91

+0.68

(+1.99%)

as on

IDEAYA Biosciences Common Stock Stock Performance

as on June 24, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $33.81
    $35.62
    downward going graph

    3.15%

    Downside

    2.03%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $20.50
    $39.28
    downward going graph

    41.28%

    Downside

    12.52%

    Upside

    downward going graph

IDEAYA Biosciences Common Stock share price movements today

Previous Close
$34.23
Open
$34.20
Volume
1.5M
Day's Low - High
$33.81 - $35.62
52 Week Low - High
$20.50 - $39.28

IDEAYA Biosciences Common Stock Historical Returns

1 Month Return
+ 19.97 %
3 Month Return
+ 14.35 %
1 Year Return
+ 60.28 %
3 Year Return
+ 42.61 %
5 Year Return
+ 60.73 %

IDEAYA Biosciences Common Stock Stock Fundamentals & Key Indicators

Check IDEAYA Biosciences Common Stock market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.3B

EPS (TTM)

-4.3065

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-180.7M

Revenue (TTM)

225.3M

Profit Margin

-62.17%

Return On Equity TTM

-14.28%

IDEAYA Biosciences Common Stock vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of IDEAYA Biosciences Common Stock with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
IDEAYA Biosciences Common Stock image
IDEAYA Biosciences Common Stock
BUY$3.3B60.73%NA-62.17%NA
Alnylam Pharmaceuticals Common Stock image
Alnylam Pharmaceuticals Common Stock
BUY$38.2B65.93%71.9612.55%NA
Vertex PharmaceuticalsCommon Stock image
Vertex PharmaceuticalsCommon Stock
BUY$118.5B144.05%27.735.51%NA
Regeneron Pharmaceuticals Common Stock image
Regeneron Pharmaceuticals Common Stock
BUY$64.2B13.51%14.9529.65%0.59%

Stock Returns calculator for IDEAYA Biosciences Common Stock Stock including INR - Dollar returns

The IDEAYA Biosciences Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

IDEAYA Biosciences Common Stock investment value today

Current value as on today

₹1,75,382

Returns

₹75,382

(+75.38%)

Returns from IDEAYA Biosciences Common Stock Stock

₹60,285 (+60.28%)

Dollar Impact

₹15,097 (+15.1%)

Analyst Recommendation on IDEAYA Biosciences Common Stock Stock

Based on 17 analysts

BUY

94.12%

Buy

5.88%

Hold

0.00%

Sell

Based on 17 analysts, 94.12% of analysts recommend a 'BUY' rating for IDEAYA Biosciences Common Stock. Average target price of $52.79

IDEAYA Biosciences Common Stock Share Price Target

Get share price movements and forecasts by analysts on IDEAYA Biosciences Common Stock.

What analysts predicted

33.87%UPSIDE

Target Price

$52.79

Current Price

$34.91

Analyzed by

17 Analysts

Target

$52.79

IDEAYA Biosciences Common Stock target price $52.79, a slight upside of 33.87% compared to current price of $34.91. According to 17 analysts rating.

Indian Investors' Interest in IDEAYA Biosciences Common Stock Stock

Search interest for IDEAYA Biosciences Common Stock Stock has decreased by -8% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-8% versus previous 30 day period

IDEAYA Biosciences Common Stock Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
3
-
-
-
7
-
-
207
10
6
Gross Profit
2
-1
-1
-1
6
-70
-74
124
10
5
Operating Income
-41
-51
-64
-66
-144
-84
-88
108
-94
-108
EBITDA
-32
-51
-51
-50
-129
-70
-76
120
-82
-97
Interest Expense
25
-
-
-
-
-
-
-
-
-
Depreciation
1
1
1
1
0
1
1
1
1
1
Income Before Tax
-33
-39
-52
-51
-130
-71
-77
119
-83
-98
Income Tax Expense
5
-1
-1
-
-
-
-
-
-
-
Net Income
-33
-39
-52
-51
-130
-71
-77
119
-83
-98
Net Profit Margin
-865.54%
0.00%
0.00%
0.00%
-1861.60%
0.00%
0.00%
57.37%
-765.66%
-1502.12%

IDEAYA Biosciences Common Stock Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
19
27
50
23
7
218
Gross Profit
0
0
-1
19
27
50
19
3
214
Operating Income
-14
-36
-44
-35
-50
-62
-134
-326
-159
EBITDA
-11
-33
-43
-33
-48
-60
-108
-270
-109
Interest Expense
-
-
-
0
0
3
21
-
-
Depreciation
0
0
1
1
1
2
4
3
4
Income Before Tax
-11
-34
-41
-34
-49
-58
-112
-274
-113
Income Tax Expense
0
2
-3
-2
-2
-3
3
-
-
Net Income
-11
-34
-38
-32
-47
-54
-112
-274
-113
Net Profit Margin
0.00%
0.00%
0.00%
-165.14%
-170.11%
-107.61%
-483.05%
-3921.10%
-51.99%

IDEAYA Biosciences Common Stock Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-39
-52
-51
-130
-72
-77
119
-83
-98
Operating Cash Flow
-43
-32
-49
-121
-60
-62
142
-90
-75
Investing Cash Flow
-
68
-20
-197
79
45
41
-97
118
Financing Cash Flow
349
39
286
2
26
1
0
2
1
Change in Cash
-48
74
217
-316
45
-15
184
-186
44

IDEAYA Biosciences Common Stock Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-34
-41
-34
-49
-58
-112
-274
-113
Operating Cash Flow
-27
-39
55
-55
-87
-115
-247
-71
Investing Cash Flow
-63
2
-146
-69
-33
-158
-502
69
Financing Cash Flow
105
50
128
145
97
362
677
29
Change in Cash
14
13
37
20
-23
89
-72
28

Global Institutional Holdings in IDEAYA Biosciences Common Stock

Funds
Holdings
Capital Research Global Investors
5.88%
Citadel Advisors Llc
1.5%
UBS Group AG
1.2%
Baker Bros Advisors LP
4.5%
Logos Global Management LP
3.93%
See all

IDEAYA Biosciences Common Stock News & Key Events

    Insights on IDEAYA Biosciences Common Stock

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Best in 3 Years

      img

      In the last 3 years, IDYA has outperformed top 5 stocks with highest market-cap in its industry

    • imgPOSITIVE IMPACT

      Best in 1 Year

      img

      In the last 1 year, IDYA has outperformed top 5 stocks with highest market-cap in its industry

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 7 days, IDYA stock has moved up by 11.7%

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 3 quarters, 207.83M → 6.56M (in $), with an average decrease of 67.2% per quarter

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 3 quarters, 119.24M → -98.53M (in $), with an average decrease of 94.1% per quarter

    About IDEAYA Biosciences Common Stock

    IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-R
    OrganisationIDEAYA Biosciences Common Stock
    Headquarters5000 Shoreline Court, South San Francisco, CA, United States, 94080
    IndustryBiotechnology
    CEODr. Joshua Bleharski Ph.D.
    E-voting on sharesClick here to vote

    Key Management of IDEAYA Biosciences Common Stock

    Name

    Title

    Dr. Joshua Bleharski Ph.D.

    Chief Financial Officer

    Mr. Andres Ruiz Briseno CPA

    Chief Accounting Officer

    Dr. Paul A. Barsanti Ph.D.

    Chief Technology Officer

    Mr. Stuart C. Dorman

    Chief Commercial Officer

    Mr. Daniel A. Simon

    Chief Business Officer

    Dr. Michael A. White Ph.D.

    Chief Scientific Officer

    Mr. Douglas B. Snyder

    Chief Legal Officer

    Dr. Darrin M. Beaupre M.D., Ph.D.

    Chief Medical Officer

    Ms. Francine Zelaya

    Senior VP & Head of Human Resources

    Mr. Mick O'Quigley

    Senior Vice President of Medical Writing & Project Management

    FAQs

    What is IDEAYA Biosciences Common Stock share price today?

    IDEAYA Biosciences Common Stock share price today is $34.91 as on at the close of the market. IDEAYA Biosciences Common Stock share today touched a day high of $35.62 and a low of $33.81.

    What is the 52 week high and 52 week low for IDEAYA Biosciences Common Stock share?

    IDEAYA Biosciences Common Stock share touched a 52 week high of $39.28 on and a 52 week low of $20.5 on . IDEAYA Biosciences Common Stock stock price today i.e. is closed at $34.91,which is 11.13% down from its 52 week high and 70.29% up from its 52 week low.

    What is IDEAYA Biosciences Common Stock's market capitalisation today?

    IDEAYA Biosciences Common Stock market capitalisation is $0.00T as on .

    How to invest in IDEAYA Biosciences Common Stock Stock (IDYA) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for IDEAYA Biosciences Common Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in IDEAYA Biosciences Common Stock Shares that will get you 0.0430 shares as per IDEAYA Biosciences Common Stock share price of $34.91 per share as on June 24, 2026 at 8:46 am IST.

    What is the minimum amount required to buy IDEAYA Biosciences Common Stock Stock (IDYA) from India?

    Indian investors can start investing in IDEAYA Biosciences Common Stock (IDYA) shares with as little as ₹94.735 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹947.35 in IDEAYA Biosciences Common Stock stock (as per the Rupee-Dollar exchange rate as on ). Based on IDEAYA Biosciences Common Stock share’s latest price of $34.91 as on June 24, 2026 at 8:46 am IST, you will get 0.2865 shares of IDEAYA Biosciences Common Stock. Learn more about fractional shares .

    What are the returns that IDEAYA Biosciences Common Stock has given to Indian investors in the last 5 years?

    IDEAYA Biosciences Common Stock stock has given 60.73% share price returns and 27.69% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?